Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach

Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach

Despite the observed clinical benefits of nirmatrelvir/ritonavir (NMV/r), it is uncertain whether Taiwan will continue covering NMV/r for high-risk individuals with mild-to-moderate coronavirus disease 2019 (COVID-19). This analysis assessed the impact of sustained utilization of NMV/r on COVID-19-a...

Full description

Saved in:
Bibliographic Details
Main Authors: Matthew Sussman, Jennifer Benner, Tendai Mugwagwa, Jackie Lee, Sheng-Tzu Hung, Ya-Min Yang, Yixi Chen
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Journal of Market Access & Health Policy
Subjects:
coronavirus disease 2019
COVID-19
nirmatrelvir
nirmatrelvir/ritonavir
clinical burden
model
Online Access:https://www.mdpi.com/2001-6689/12/4/26
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items